OCREVUS Patient Navigators
Your OCREVUS Patient Navigator is your point of contact for assistance during your patients’ treatment, including access, reimbursement and infusion coordination support.
Patient Navigators can help you with:
Answer questions you or your patients may have throughout the enrollment process.
Help identify patient assistance options for eligible patients.
Benefits investigations (BIs)
Walk your patients through the results of their BIs and help them understand next steps.
- Confirm an appropriate infusion site
- Work with you and your patients to schedule infusions
- Walk patients through an infusion checklist to help them prepare for treatment
Prior authorizations (PAs)
- Help you identify if a PA is necessary
- Offer resources as you obtain PAs for your patients
- Follow up with the payer regarding PA status
- Provide PA forms
Automatic benefits reverification
- Reverify patients’ benefits prior to their next scheduled infusion
- Coordinate with patients, practices and infusion sites (if applicable) to schedule the next infusion
The completion and submission of coverage- or reimbursement-related documentation are the responsibility of the patient and health care provider. Genentech makes no representation or guarantee concerning coverage or reimbursement for any service or item.
PAN=Patient Authorization and Notice of Request for Transmission of Health Information to Genentech Access Solutions and Genentech® Access to Care Foundation.
SMN=Statement of Medical Necessity.
Important Safety Information & Indication
OCREVUS is indicated for the treatment of adult patients with relapsing or primary progressive forms of multiple sclerosis.
OCREVUS is contraindicated in patients with active hepatitis B virus infection and in patients with a history of life-threatening infusion reaction to OCREVUS.
Warnings and Precautions
Management recommendations for infusion reactions depend on the type and severity of the reaction. Permanently discontinue OCREVUS if a life-threatening or disabling infusion reaction occurs.
Delay OCREVUS administration in patients with an active infection until the infection is resolved. Vaccination with live-attenuated or live vaccines is not recommended during treatment with OCREVUS and after discontinuation, until B-cell repletion.
An increased risk of malignancy, including breast cancer, may exist with OCREVUS.
Most Common Adverse Reactions
RMS: The most common adverse reactions in RMS trials (incidence ≥10% and >REBIF): upper respiratory tract infections and infusion reactions.
PPMS: The most common adverse reactions (≥10% and >placebo): upper respiratory tract infections, infusion reactions, skin infections, and lower respiratory tract infections.